Identification of specificity‐determining residues in antibodies

The successful identification of the residues that contact ligand has important implications, especially in view of the increasing use of antibodies in various medical and industrial applications. Analysis of the crystallographically derived, three‐dimensional structures of five antibody‐antigen complexes and of the available amino acid sequence data on antibody variable regions reveals that the residues that contact antigen are in the main also the most variable. It is proposed that a good first guess of the identity of the specificity‐determining residues can be made from an examination of the variability values at sequence positions. New boundaries for the complementarity‐determining regions are proposed.—Padlan, E. A., Abergel, C., Tipper, J. P. Identification of specificity‐determining residues in antibodies. FASEB J. 9, 133‐139 (1995)

[1]  I. Pastan,et al.  Recombinant toxins for cancer treatment. , 1991, Science.

[2]  H. Huland,et al.  [Monoclonal antibodies in diagnosis and therapy]. , 1989, Immunitat und Infektion.

[3]  T. Bhat,et al.  Bound water molecules and conformational stabilization help mediate an antigen-antibody association. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  E. Kabat,et al.  The Structural Basis for Antibody Complementary , 1978 .

[5]  E. Kabat,et al.  The structural basis of antibody complementarity. , 1978, Advances in protein chemistry.

[6]  R. Grantham.  Amino Acid Difference Formula to Help Explain Protein Evolution , 1974, Science.

[7]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[8]  H. Bilofsky,et al.  Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites. , 1977, The Journal of biological chemistry.

[9]  E. Padlan,et al.  Structural significance of sequence variability in antibody complementarity-determining regions. , 1994, Research in immunology.

[10]  B C Finzel,et al.  Three-dimensional structure of an antibody-antigen complex. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1978, Archives of biochemistry and biophysics.

[12]  G. Cohen,et al.  Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[13]  E A Padlan.  Structural implications of sequence variability in immunoglobulins. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H Franz,et al.  [Monoclonal antibodies in diagnosis and therapy]. , 1989, Die Pharmazie.

[15]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Boulianne,et al.  Production of functional chimaeric mouse/human antibody , 1984, Nature.

[17]  T. T. Wu,et al.  Length distribution of CDRH3 in antibodies , 1993, Proteins.

[18]  E. Padlan,et al.  Antibody-antigen complexes. , 1988, Annual review of biochemistry.

[19]  M. L. Connolly.  Analytical molecular surface calculation , 1983 .

[20]  E. Padlan,et al.  A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. , 1991, Molecular immunology.

[21]  L. Prasad,et al.  Structure determination of a monoclonal Fab fragment specific for histidine-containing protein of the phosphoenolpyruvate: sugar phosphotransferase system of Escherichia coli. , 1988, The Journal of biological chemistry.

[22]  T. T. Wu,et al.  AN ANALYSIS OF THE SEQUENCES OF THE VARIABLE REGIONS OF BENCE JONES PROTEINS AND MYELOMA LIGHT CHAINS AND THEIR IMPLICATIONS FOR ANTIBODY COMPLEMENTARITY , 1970, The Journal of experimental medicine.

[23]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[24]  W G Laver,et al.  Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. , 1992, Journal of molecular biology.

[25]  M Karplus,et al.  Side-chain torsional potentials: effect of dipeptide, protein, and solvent environment. , 1979, Biochemistry.

[26]  J. Schlom.  Basic principles and applications of monoclonal antibodies in the management of carcinomas: the Richard and Hinda Rosenthal Foundation award lecture. , 1986, Cancer research.

[27]  D. Burton,et al.  Localization of the binding site for the human high-affinity Fc receptor on IgG , 1988, Nature.

[28]  R. Poljak,et al.  Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution , 1986, Science.

[29]  J. N. Varghese,et al.  Three-dimensional structure of a complex of antibody with influenza virus neuraminidase , 1987, Nature.

[30]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.